FRI0301 Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases – Bone Mineral Density Increase in Lumbar Spine is Negatively Correlated with Baseline Oral Prednisolone Dose and Predicted by Decreasing Rate of Serum Undercarboxylated Osteocalcin at 6 Months

Abstract

BackgroundReceptor activator of nuclear factor kappa-B ligand (RANKL) is a key inducer of osteoclast differentiation and activation, which plays a crucial role in osteoporosis and bone erosion of rheumatic diseases....